Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts

Melissa J. McDonnell, S. Aliberti, Pieter C. Goeminne, K. Dimakou, Stefano C. Zucchetti, J. Davidson, C. Ward, John G. Laffey, Simon Finch, A. Pesci, Lieven J. Dupont, Thomas C. Fardon, Dusan Skrbic, Darja Obradovic, Sarah Cowman, Michael R. Loebinger, Robert M. Rutherford, Anthony De Soyza, James D. Chalmers

Research output: Contribution to journalArticle

Abstract

Introduction Bronchiectasis is a multidimensional disease associated with substantial morbidity and mortality. Two disease-specific clinical prediction tools have been developed, the Bronchiectasis Severity Index (BSI) and the FACED score, both of which stratify patients into severity risk categories to predict the probability of mortality. Methods We aimed to compare the predictive utility of BSI and FACED in assessing clinically relevant disease outcomes across seven European cohorts independent of their original validation studies. Results The combined cohorts totalled 1612. Pooled analysis showed that both scores had a good discriminatory predictive value for mortality ( pooled area under the curve (AUC) 0.76, 95% CI 0.74 to 0.78 for both scores) with the BSI demonstrating a higher sensitivity (65% vs 28%) but lower specificity (70% vs 93%) compared with the FACED score. Calibration analysis suggested that the BSI performed consistently well across all cohorts, while FACED consistently overestimated mortality in 'severe' patients ( pooled OR 0.33 (0.23 to 0.48), p<0.0001). The BSI accurately predicted hospitalisations ( pooled AUC 0.82, 95% CI 0.78 to 0.84), exacerbations, quality of life (QoL) and respiratory symptoms across all risk categories. FACED had poor discrimination for hospital admissions ( pooled AUC 0.65, 95% CI 0.63 to 0.67) with low sensitivity at 16% and did not consistently predict future risk of exacerbations, QoL or respiratory symptoms. No association was observed with FACED and 6 min walk distance (6MWD) or lung function decline. Conclusion The BSI accurately predicts mortality, hospital admissions, exacerbations, QoL, respiratory symptoms, 6MWD and lung function decline in bronchiectasis, providing a clinically relevant evaluation of disease severity.

Original languageEnglish
Pages (from-to)1110-1118
Number of pages9
JournalThorax
Volume71
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts'. Together they form a unique fingerprint.

  • Cite this

    McDonnell, M. J., Aliberti, S., Goeminne, P. C., Dimakou, K., Zucchetti, S. C., Davidson, J., Ward, C., Laffey, J. G., Finch, S., Pesci, A., Dupont, L. J., Fardon, T. C., Skrbic, D., Obradovic, D., Cowman, S., Loebinger, M. R., Rutherford, R. M., De Soyza, A., & Chalmers, J. D. (2016). Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts. Thorax, 71(12), 1110-1118. https://doi.org/10.1136/thoraxjnl-2016-208481